Member Info for B2HS2L

Covid-19 Rapid Antigen Pro sensitivity and specificity updated recently.

Possibility that Covid-19 Rapid Antigen test sensitivity and specificity updates are now available, prior to launch at show.

Neil, -
Found the problem.

My notes contain the text on the video-
"We also have a direct sales force that will be focusing"
What he says is different:
"We WILL also have a direct sales force that will be focusing"

I can only apologies for the misunderstanding.
It will soon be made clear what we have in the USA I believe, thanks for bringing the matter up.

No probs Brent. - Look after yourselves in Chicago, sorry to hear you need to travel that far for treatment.
Worlds busiest airport I believe.

No room left, but yes Liz has moved on, but she was busy in South America for us.

neil, -
Kevin's "We also have a direct sales force that will be focussing on expanding our distributor network."

From:
August 2021 - Novacyt Investor Meeting. - Q&A
http://novacyt.com/wp-content/uploads/2021/09/Investor-meeting-QA-August-2021-ENG.pdf

6. How does the distribution network work? Novacyt’s sales force seems very strong in the UK,
with heavy recruitment, but how big/effective are the distributors in the rest of the world?

GM: As previously presented, we have a very well-established distributor network, with more than 400 distributors
currently. This distributor network is essential for our growth strategy going forward. The channel
represented approximately 35% of our business, without the DHSE contract, in the first half of the year. Its
geographical distribution is also very well balanced, with revenues in the Americas, including Latin America,
of approximately 30%; EMEA, which includes Europe, Middle East and Africa, with approximately 55% – of
which 25% is UK and Ireland – and in Asia we have 15% of our distributor business.
The indirect sales channel is one of our key enablers for our global presence. If we look into our direct sales,
it generated 65% of revenues, again without the DHSE contract, in the first half of 2021. As mentioned
during my presentation, a well-balanced sales channel mix will enable our future growth. Increasing our
market access is a key pillar of our commercial strategy in increasing our share of all of that customer base
and generating market share gains.

+++
Whilst the US direct sales team has only one product that has EUA to sell, Kevin is getting them to expand the network. Seems reasonable in the circumstances, but direct sales represents a bigger chunk of our income as stated above.
Also

Liz F.
Business Development - Latin America
Dates EmployedJan 2010 – Feb 2020
Employment Duration10 yrs 2 mos
LocationUnited Kingdom
Offered a part-time agreement to develop sales for the group focused on the Latin American Region. It allowed continuous development at GESS Technologies while also developing new business for Lab 21.

Key Accomplishments:

Sales Growth – Successfully closed one of the largest business the company had ever sold in single transaction. Led increase of annual sales of existing distributors network first established by Plasmatec. Led distributor selection and set payment terms and conditions.

Territory Expansion – Developed a sales and marketing strategy plan that identified new distributors in Mexico, Panama, Dominican Republic, Honduras, Guatemala, Colombia, Ecuador, Brazil, Uruguay, Bolivia, Peru and Chile.

Regulatory Compliance – Managed all technical documentation, certifications and contracts required to support local registration and meet local Ministry of Health requirements in each country for new distributors.

Uggy, I can imagine DA was not happy with certain people doing certain jobs, and that would take time to sort out.
He has had 3 months to do that now, and some of the higher management changes have been observed on LinkedIn.
It's time for that to be formalised, - even if outsiders are on gardening leave awaiting a start at Novacyt.

USA, - do we have a direct sales team and what is it's performance.
I note in the 18.10.2021 video to support the virtual meeting of ASHG21 that Kevin Crittenton discussed USA sales and stated "We also have a direct sales force that will be focussing on expanding our distributor network." - so how big is it (10?), where is it situated, and what has been it's performance.

I agree, DA's refusal to engage with shareholders is quite disgraceful.

Agree with the second part.
IMO if the board aren't interested in an offer or the sp, they will maintain the status quo.

Not expecting too much at the end of January in the way of fresh information, but they must update on IT-IS sales to TATA, and it's time for a video from DA, - nothing less will do.

_Mr_Big -

"What really bothers me, is why do they not care about IIs. Still no II support despite cash in bank, revenues,
profits and strong R&D."

I think the answer is confidence.

The BoD are confident:

1 they won't need to raise cash in the forseable future.

2 they know how much the business is worth, and could demonstrate it's value to shareholders should a bid arrive
in the post / be made public.

3 they know they have taken into account the financial problems created by the DHSC dispute, and are confident
they will win in the end.

So they just plough on with the plan to create a Mid-Cap status company, the difference being they know what
it's worth, shareholders don't, and this way - neither do those venturing a bid.

What's important IMO is that should it be necessary, shareholder value will be revealed, but the bid will have to be good to match the companies valuation of the R&D and Informatics teams.

Wasn't that the problem of King Charles the first?
Answerable for his actions only to God?
That didn't end well as I recall,
..and a dictator succeeded him

https://www.linkedin.com/in/modern-tech-for-medical-supplies-730274226/

Modern Tech For Medical Supplies

Amman, Jordan

About
Modern Tech for Medical Supplies; is one of Modern tech group representing a trading company (modern tech for medical supplies), Modern Labs for food testing and modern code for information and technology.

In our trading company, we are representing BIOTECON were we build an amazing market share in the private laboratories and food factories also with the public sector including JFDA (Jordanian Food and Drugs administration)

Also we have an amazing network among the food industries were we are representing 3M food safety line for the (3M Indicators , products sampling and MDS instrument) were we are dealing with many the factories and laboratories across Jordan.

We are representing also LABTRON, and we are having an increasing market share since we started representing this brand in 2019

For Laboratories equipping projects, we have installed many labs with PCR in the private labs and private food industry from our partner IT-IS (before it was acquisitioned by Novacyt group recently)

This Jordan based company is not mentioned here: http://www.primerdesign.co.uk/about/distributors

...It seems likely that WHO has introduced our tests into the SE Asia region, and I hope to establish that Novacyt has been able to sell assays and instruments into the region in larger amounts this month.

Early Jan:
https://indianewsrepublic.com/testing-capabilities-are-diversifying-in-the-who-southeast-asia-region-omicron-drives-genome-sequencing-health-news-et-healthworld/605157/

Testing capabilities are diversifying in the WHO Southeast Asia region.
Omicron Drives Genome Sequencing, Health News, ET HealthWorld

New Delhi: In the third year of the COVID-19 pandemic, the World Health Organization (WHO) will enable countries in the Southeast Asian region to continue to test the laboratory’s ability to test one of its key priorities, SARS-CoV2. Notified that it has been strengthened. .. Rapid detection of Omicron in countries in the region has enhanced the capabilities of laboratories with limited molecular testing and genomic sequencing at the start of the pandemic.
The World Health Organization’s Southeast Asia Regional Office (WHO SEARO) said the number of laboratories testing SARS-CoV2 has increased from five at the start of the pandemic to now over 48,000.

Currently, eight of the 11 countries in the region have laboratories conducting genome sequencing, and while all countries have external access to such facilities, two more are domestic. We are in the process of establishing our ability to sequence genomes.

WHO SEARO said it worked with partners to work with regional member states to set, extend and enhance testing capabilities to subnational levels, making testing accessible to everyone from anywhere. We assisted in training the labor force in the laboratory, procuring laboratory equipment, diagnosing, enhancing reagents and data management systems, and transporting samples.

“Diagnostic services are important to public health. In the event of an outbreak, timely information is needed to guide and coordinate public health responses to stop or reduce the spread of the disease. Therefore, since the outbreak of COVID-19. One of the key areas of WHO support was to enhance testing capabilities with a focus on addressing inequality in access to COVID-19 diagnostic tools, “said Dr. Poonam Khetrapal Singh, Regional Director. I am saying. WHO Southeast Asia region.

In addition to strengthening the capabilities of the National Institutes Network, WHO SEARO also said it helped expand testing capabilities to the local level to increase access to testing at the community level throughout the region. .. This was achieved through collaboration between sectors involving academia, the animal sector, and the private sector, as well as the integration of existing laboratory networks and infrastructure.

Partnerships through regional, regional, or international expertise have led to a surge in countries with COVID-19 cases, resulting in rapid labor deployment, technology transfer, and stronger coordination to meet growing test demand....
+++

It seems likely that WHO has introduced our tests into the SE Asia region, and I hope to establish that Novacyt has been able to sell assays and instruments into the region in larger amounts in th

JRDC -
How likely is it that the company will try stating revenue for the next 6 months, not the next year?
It would make a little more sense for me a least.

Having trawled LinkedIn, it is clear there have been people moving on to new positions within Novacyt, some with promotions.
It may be that DA has focused on creating these positions, fearing that he may lose staff if he did not do so.
If that is right, then it would have taken time to achieve, and necessary as there is so much competition for trained life sciences experienced personnel from competitors, particularly in southern england.

Have a look at this, - You Med Ltd - https://www.youmed.co.uk/diagnostics
It would not surprise me if we supplied them.

Kaeren / Saintsmith

wrt IT-IS directors bonus: Achieving manufacturing targets subsequent to October 2021 buyout by Novacyt:

RNS 15.10.2020
"Terms of the acquisition

Under the terms of the acquisition, £10.1 million in cash will be paid upfront by the Company for the entire issued share capital of IT-IS and for the business assets of IT-IS Life Science (Ireland) Limited. The initial consideration of £10.1 million will be reduced by £3.6 million of cash on the balance sheet of IT-IS at completion resulting in net cash consideration of £6.5 million. In addition, an earn out of up to £1.9 million in cash is payable to the directors of IT-IS over the next two years, subject to certain manufacturing targets being achieved."

RNS 27.09.2021
"- Payment of the first earn-out milestone related to the IT-IS International acquisition"
+++

Second earn-out milestone due Sept / Oct 2022.

+++

Kaeren, re your IT-IS new faces post:

There are some very well qualified new arrivals big hitters in their specialities in Southampton (I believe)

https://www.linkedin.com/in/gem-mcluckie-a1aab79/

https://www.linkedin.com/in/scott-kimber-861668152/

https://www.linkedin.com/in/callum-pickett-5aa346200/

Unfortunately Achillios Neophytou has moved to You Med Ltd.

Source: genomeweb

Cue Health said this week that it will develop an Omicron genotyping test for COVID-19. The test, which will be for professional use at the point of care, is being developed as part of the company's ongoing work with the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority, the San Diego-based firm said, adding it received additional funding from BARDA for the initiative. Cue Health did not disclose the amount of the funding but said it will go toward accelerating the development, validation, and regulatory authorization of a single-plex assay created solely to detect the Omicron variant in nasal samples. The test will be compatible with the Cue Health Monitoring System and the Cue Health mobile app. In March, the firm received the first US Food and Drug Administration Emergency Use Authorization for a molecular, at-home COVID-19 test for use without a doctor's prescription.

The American government supporting yet more indigenous molecular diagnostics USA companies with BIG money (Cue have taken in hundreds of millions) to develop, scale and roll out. These grants are then followed by large commercial contracts to ensure those development tax-payers dollars are not wasted and the profits remain on shore. That’s joined up thinking and not exactly rocket science.
++++
Why can't UK do that?

If Covid any diagnostic stocks report before us, showing good profitability, our sp will climb.

https://content.next.westlaw.com/8-614-6926?__lrTS=20210212021953119&transitionType=Default&contextData=(sc.Default)&firstPage=true

Shareholders' rights in private and public companies in France: overview
by Raphaël Dana and Christopher Anderson, Dana Associés

Law stated as at 01 Feb 2021

Para. 28.
What information about the company do the directors have to disclose under securities laws (where applicable)?

In addition to the annual and half-year reports that listed companies must provide each year, a listed company must also comply with the permanent information requirements of the French stock exchange authority (Autorité des Marchés Financiers) (AMF) (www.amf-france.org/en).
Listed companies must disclose to the public AS SOON AS POSSIBLE any privileged information. This is information of a precise nature that has not been made public, relating directly or indirectly to one or more issuers of financial instruments, or to one or more financial instruments, which, if made public, would be likely to have a significant effect on the price of the relevant financial instruments or of related financial instruments. In other words, privileged information is a type of information that can be the basis for a decision to invest.
Further, a listed company preparing a financial transaction that is likely to have a significant impact on the market price of a financial instrument, or on the financial position and rights of holders of that financial instrument, must disclose the characteristics of the transaction to the public as soon as possible.
Any change to privileged information must also be disclosed to the public.
Further, listed companies must ensure that the same information disclosed abroad is disclosed simultaneously in France.
+++

Many other paragraphs are of interest to share holders.

FWIW Poidster - I would suggest that the following are relevant to any communication:

PI's cannot survive / the sp cannot be sustained, on the level of information being made available beyond the half and full year results.

That leaves investors feeling unsupported, particularly when shorters are active.

Investors are left believing that Novacyt does not implement the mandatory requirement to RNS (not tweet) news which will move the sp if made available immediately, as the boards of all AIM companies are required to do.

If you need any assistance with this task, please advise, happy to help.

Been here most of the day, so signing off for tonight.

August 2021 - Novacyt Investor Meeting. - Q&A
http://novacyt.com/wp-content/uploads/2021/09/Investor-meeting-QA-August-2021-ENG.pdf

https://novacyt.com/wp-content/uploads/2021/06/Novacyt-2020-Full-Year-Results-Strategy-update-Final-website-version-for-29.06.2021-1.pdf (p11-17).

Our problem is that these documents to some extent contain intent beyond Covid-19 products, and were created before DA arrived.

Because
a) we have a new CEO,
b) we have no update since his arrival
c) we assume that no change to the DHSC standoff has taken place
we don't know to what extent these past plans have been affected by the new CEO's arrival.
IMO it is vital that a video is available in which the new CEO reiterates old plans and discusses any new plans.
Without that we PI's could be forgiven from believing that DA does not care about PE engagement of any kind.

Must haves:
a) news on Co-Prep
b) news on DHSC dispute (else we are to think its done and dusted financially, and we are'nt to hear any more about it
c) news on IT-IS sales to India / tie up with TATA.

PI's cannot survive / the sp cannot be sustained, on the level of information being made available beyond the half and full year results.
Not many new investors are going to invest if there is no news on their investment.

I dug up a RNS statement today concerning the creation a USA based sales team, which implied a timetable.
Many other such examples of implied timetables are contained within RNS's, (Co-Prep).
We absolutely need to know about the status of these projects, nothing else will do.